Author pages are created from data sourced from our academic publisher partnerships and public sources.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed… Expand
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
- B. Druker, F. Guilhot, +29 authors R. Larson
- The New England journal of medicine
- 7 December 2006
BACKGROUND The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa… Expand
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
- M. Baccarani, Jorge Cortes, +17 authors R. Hehlmann
- Journal of clinical oncology : official journal…
- 10 December 2009
PURPOSE To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs),… Expand
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic myeloid leukemia (CML). Although experience is too limited to permit evidence-based evaluation of survival, the… Expand
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
BACKGROUND Imatinib treatment significantly improves survival in patients with chronic myeloid leukaemia (CML), but little is known about whether treatment can safely be discontinued in the long… Expand
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic phase. We here describe the correlation of imatinib trough plasma concentrations (C(mins)) with clinical… Expand
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blast crisis is the most advanced stage of chronic myelogenous leukemia (CML) and is highly refractory to therapy. CML is caused by expression of the chimeric BCR-ABL tyrosine kinase oncogene, the… Expand
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Chronic myelogenous leukemia (CML) is caused by expression of the BCR-ABL tyrosine kinase oncogene, the product of the t(9;22) Philadelphia translocation. Patients with CML in accelerated phase have… Expand
International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in…
Abstract 1126 Poster Board I-148 Background The IRIS study demonstrated superior safety and efficacy of imatinib (IM) relative to interferon-αa + cytarabine. Based on results from this trial, IM is… Expand
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.
- J. E. Cortes, D.-W. Kim, +27 authors H. Kantarjian
- The New England journal of medicine
- 6 November 2013
BACKGROUND Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at… Expand